3 completed, 1 recruiting, 1 unknown. 2 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Amelogenin: new trials by email Literature Review of Amelogenin trials Research Report on Amelogenin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regenerative Gel (Emdogain®) for Healing After Wisdom Tooth Extraction Enamel Matrix Derivative (Emdogain®) - Alveolar Bone Loss, Periodontal Pocket | Not applicable | Recruiting | Aristotle University Of Thessaloniki | 70 | 2026-03-09 | 2026-07-22 |
| Treatment of Intraosseous Periodontal Defects With Amelogenins MINSD and amelogenins, MINSD - Periodontal Bone Loss, Periodontal Pocket | Not applicable | Unknown | Federico II University | 22 | 2023-02-01 | 2024-02-28 |
| AMG 334 20160172 Pediatric Migraine PK Study. AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3 - Migraine | Phase 1 | Completed | Amgen | 53 | 2018-05-04 | 2024-05-28 |
| Verify if Amelogenins Had Some Benefits in Improving Lower 2nd Molar Periodontal Healing After 3rd Molar Extraction Amelogenin, Placebos - Attachment Loss, Periodontal, Teeth, Impacted | Phase 4 | Completed | University of Roma La Sapienza | 5 | 2016-03-24 | 2020-03-19 |
| Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks - Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | Phase 2 | Completed | Amgen | 111 | 2005-01-01 | 2011-01-24 |
Periodontal Pocket (3) · Alveolar Bone Loss (2) · Migraine Disorders (1) · Multiple Myeloma (1) · Periodontal Attachment Loss (1) · Tooth, Impacted (1)
Amgen (2) · Aristotle University Of Thessaloniki (1) · Federico II University (1) · University of Roma La Sapienza (1)
Greece (1) · Italy (1) · United States (1)
Luca Ramaglia (1) · Roberto Pippi, MDDS (1)